Encorafenib Plus Binimetinib for BRAF-Mutated Metastatic Melanoma: 7-Year Follow-Up Data From the COLUMBUS Trial

The 7-year follow-up data for encorafenib/binimetinib showing that around 21% of patients remained progression-free supports BRAF/MEK inhibition as a later treatment option after immunotherapy failure, but doctors are reluctant to stop BRAF/MEK inhibitors given lack of data, even in those patients doing well long-term on the medications with minimal toxicity.

Related Keywords

,Expert Perspectives ,Plus Binimetinib ,Mutated Metastatic Melanoma ,Year Follow Up Data From ,Melanoma ,Melanoma Treatments ,Braf Mutation ,Targeted Therapies ,Immunotherapy ,Brain Metastases ,Clinical Trials ,Pd 1 Resistant Melanoma ,Patient Population ,Unmet Need ,Adjuvant Therapy ,